Find a Research Expert

Experts
 Menu

Darran P O'Connor

Institution

Royal College of Surgeons in Ireland

Contact

Subjects

Biochemistry

Medicine & Nursing

Details
Publications 43
As first author 3
As last author 7
Unique topics 346
Collaborations 88
Patents 1
Sources 7
Are you Darran P O'Connor? Click here to provide feedback on your profile.
All
2017
2016
2015
2014
2013
2012
2011
2010
2009
Earlier
All
2017
2016
2015
2014
2013
2012
2011
2010
2009
Earlier

2017

BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.
2017

Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney.
2017

Epigenome-wide SRC-1 mediated gene silencing represses cellular differentiation in advanced breast cancer.
2017

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
2017

The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.
2017

Vitamin D receptor as a target for breast cancer therapy.
2016

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
2016

Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology.
2016

Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.
2016

Biosimilars: Extrapolation for oncology.
2016

De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.
2016

Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
2016

Fam60a defines a variant Sin3a-Hdac complex in embryonic stem cells required for self-renewal.
2016

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
2016

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
2015

FKBPL: a marker of good prognosis in breast cancer.
2015

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
2014

A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.
2014

Dynamic and influential interaction of cancer cells with normal epithelial cells in 3D culture.
2014

microRNAs: a new class of breast cancer biomarkers.
2013

miRNA dysregulation in breast cancer.
2012

Ghrelin concentrations in maternal and cord blood of Type 1 diabetic and non-diabetic pregnancies at term.
2012

Identification of transcription factors associated with castration-resistance: Is the serum responsive factor a potential therapeutic target?
2012

Maternal and fetal cocaine- and amphetamine-regulated transcript in diabetic and non-diabetic pregnancy.
2012

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.
2011

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
2011

The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERĪ±, and is an independent prognostic factor in node-negative breast cancer.
2010

Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.
2010

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
2010

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
2009

Cancer proteomics--an evolving battlefield. Conference on Cancer Proteomics 2009: Mechanistic Insights, Technological Advances & Molecular Medicine.
2009

Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.
2008

Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
2007

Breast cancer proteomics: clinical perspectives.
2007

Molecular links between mammary gland development and breast cancer.
2006

Functional interrogation of breast cancer: from models to drugs.
2006

Molecular basis of cell-biomaterial interaction: insights gained from transcriptomic and proteomic studies.
2006

Proteomic analysis of factors released from p21-overexpressing tumour cells.
2005

Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction.
2001

A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than Rb.
2001

Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses?
2001

P53 CODON 72 POLYMORPHISM AND HUMAN PAPILLOMAVIRUS ASSOCIATED SKIN CANCER

These arethe7 unique sources for Darran P O'Connor's 43 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Dublin City University 4
Ireland -> Dublin City University -> PubMed 4
Ireland -> Royal College of Surgeons in Ireland 13
Ireland -> Royal College of Surgeons in Ireland -> PubMed 13
Ireland -> Trinity College Dublin 2
Ireland -> University College Dublin 24
Ireland -> University College Dublin -> PubMed 24
Nov 22, 2007

METHODS AND COMPOSITIONS FOR IDENTIFYING AND USING P21-REGULATED PROTEINS
+

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.